Kv3.1 Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Kv3.1 Protein</th>
</tr>
<tr>
<td class="label">Activation voltage</td>
<td>+10 to +30 mV</td>
</tr>
<tr>
<td class="label">Deactivation time</td>
<td>2-5 ms</td>
</tr>
<tr>
<td class="label">Activation time</td>
<td>1-2 ms</td>
</tr>
<tr>
<td class="label">Conductance</td>
<td>30-40 pS</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Activators</td>
<td>Enhance channel opening</td>
</tr>
<tr>
<td class="label">Blockers</td>
<td>Reduce channel activity</td>
</tr>
<tr>
<td class="label">Modulators</td>
<td>Allosteric regulation</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Viral vector delivery</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Introduction
Kv3.1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Kv3.1 (KCNC1) is a voltage-gated potassium channel subunit that enables fast-spiking interneurons to fire at high frequencies without adaptation. It is characterized by rapid activation and deactivation kinetics, making it essential for precise temporal coding in neuronal circuits.
...Kv3.1 Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Kv3.1 Protein</th>
</tr>
<tr>
<td class="label">Activation voltage</td>
<td>+10 to +30 mV</td>
</tr>
<tr>
<td class="label">Deactivation time</td>
<td>2-5 ms</td>
</tr>
<tr>
<td class="label">Activation time</td>
<td>1-2 ms</td>
</tr>
<tr>
<td class="label">Conductance</td>
<td>30-40 pS</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Activators</td>
<td>Enhance channel opening</td>
</tr>
<tr>
<td class="label">Blockers</td>
<td>Reduce channel activity</td>
</tr>
<tr>
<td class="label">Modulators</td>
<td>Allosteric regulation</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Viral vector delivery</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Introduction
Kv3.1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Kv3.1 (KCNC1) is a voltage-gated potassium channel subunit that enables fast-spiking interneurons to fire at high frequencies without adaptation. It is characterized by rapid activation and deactivation kinetics, making it essential for precise temporal coding in neuronal circuits.
The Kv3.1 channel, encoded by the KCNC1 gene, is a member of the Shaw-like potassium channel family (Kv3). These channels are distinguished by their unique biophysical properties, including depolarized voltage dependence and fast gating kinetics, which allow [neurons](/entities/neurons) to fire action potentials at frequencies exceeding 100 Hz without frequency-dependent depression.
Gene and Protein Structure
The KCNC1 gene is located on chromosome 11p15.5 and consists of 7 exons spanning approximately 12 kb. The protein product is 526 amino acids in length with a molecular weight of approximately 58 kDa.
Kv3.1 contains six transmembrane domains (S1-S6), with the S4 segment serving as the voltage sensor. The pore region is formed between S5 and S6 helices, containing the signature potassium channel selectivity filter (GYG). The cytoplasmic N- and C-termini contain sites for regulatory modifications including phosphorylation and protein-protein interactions.
Expression Pattern
Kv3.1 is predominantly expressed in fast-spiking interneurons throughout the central nervous system. High expression is observed in:
- Cortical interneurons: Parvalbumin-positive (PV+) fast-spiking interneurons in all cortical layers
- Hippocampal interneurons: PV+ basket cells and axo-axonic cells
- Striatal interneurons: Fast-spiking PV+ interneurons
- Thalamic reticular nucleus: Nucleus of the optic tract neurons
- Cerebellar interneurons: Molecular layer interneurons and Golgi cells
- Brainstem: Auditory brainstem neurons including bushy cells of the cochlear nucleus
In the human brain, Kv3.1 expression is particularly enriched in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and thalamus, regions critically involved in cognitive processing and sensory integration.
Molecular Function
Biophysical Properties
Kv3.1 channels exhibit several distinctive biophysical characteristics:
Role in Fast-Spiking
Kv3.1 channels enable fast-spiking interneurons to maintain high-frequency firing through:
Rapid repolarization: Fast activation and deactivation allow quick membrane potential reset after action potentials
Reduced spike frequency adaptation: Minimal use-dependent depression during sustained firing
Precise temporal precision: Enables accurate timing of inhibitory outputs
Metabolic efficiency: Reduced calcium entry through voltage-gated calcium channels due to brief action potentialsProtein-Protein Interactions
Kv3.1 interacts with several regulatory proteins:
- KChiP1-3: K+ channel interacting proteins that modulate channel trafficking and gating
- DARP32: Dopamine- and cAMP-regulated phosphoprotein, regulates Kv3.1 phosphorylation
- AKAP79/150: A-kinase anchoring proteins that target PKA to regulate channel activity
- Filamin A: Cytoskeletal protein that influences channel localization
Role in Neurodegeneration
Alzheimer's Disease
In AD, Kv3.1 dysfunction may contribute to:
- Excitatory/inhibitory imbalance: Loss of fast-spiking interneurons disrupts cortical inhibition
- Network oscillations: Impaired gamma oscillations (30-80 Hz) observed in AD models
- Synaptic plasticity deficits: Altered short-term plasticity in inhibitory circuits
Parkinson's Disease
Kv3.1 channels in the basal ganglia are affected in PD:
- Striatal interneuron dysfunction: Altered firing patterns in PV+ interneurons
- Beta oscillations: Pathological synchronization in the 13-30 Hz range
- Therapeutic implications: Kv3.1 modulators may restore normal firing patterns
Epilepsy
KCNC1 mutations cause progressive myoclonus epilepsy (PME):
- Dominant-negative effects: Mutations disrupt channel function
- Gain-of-function: Some mutations cause excessive neuronal inhibition
- Therapeutic targeting: Kv3.1 activators may restore normal excitability
Ataxia
KCNC1 mutations are associated with cerebellar ataxia:
- Purkinje neuron dysfunction: Impaired firing precision
- Motor coordination deficits: Altered cerebellar output
- Therapeutic approaches: Gene therapy and small molecule modulators
Therapeutic Implications
Drug Development Targets
Kv3.1 channels represent promising therapeutic targets:
Clinical Pipeline
- Retigabine: Kv3.1/3.2 activator (approved for epilepsy, withdrawn)
- Pyrazolopyrimidines: Novel Kv3.1 activators in preclinical development
- AAV vectors: Gene therapy approaches for KCNC1 mutations
Animal Models
Knockout Studies
- Kv3.1 KO mice: Show impaired fast-spiking, ataxia, and premature death
- Conditional KO: Region-specific knockouts reveal circuit-specific functions
- Humanized mice: Expressing disease-associated KCNC1 mutations
Disease Models
- AD models: [Amyloid-beta](/proteins/amyloid-beta) exposure reduces Kv3.1 expression
- PD models: 6-OHDA lesion alters Kv3.1 function in striatum
- Epilepsy models: Kv3.1 mutations cause spontaneous seizures
Research Directions
Current research focuses on:
Structure-function studies: Cryo-EM structures of Kv3.1 in various states
Circuit-specific targeting: Developing region-selective modulators
Gene therapy: AAV-delivered KCNC1 for channelopathies
Biomarkers: Kv3.1 expression as a biomarker for interneuron healthBackground
The study of Kv3.1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[1]: https://pubmed.ncbi.nlm.nih.gov/23400010/ PMID: 23400010(https://pubmed.ncbi.nlm.nih.gov/23400010/)
[2]: https://pubmed.ncbi.nlm.nih.gov/24563466/ PMID: 24563466(https://pubmed.ncbi.nlm.nih.gov/24563466/)
[3]: https://pubmed.ncbi.nlm.nih.gov/25849640/ PMID: 25849640(https://pubmed.ncbi.nlm.nih.gov/25849640/)
[4]: https://pubmed.ncbi.nlm.nih.gov/27426723/ PMID: 27426723(https://pubmed.ncbi.nlm.nih.gov/27426723/)
[5]: https://pubmed.ncbi.nlm.nih.gov/28645618/ PMID: 28645618(https://pubmed.ncbi.nlm.nih.gov/28645618/)
[6]: https://pubmed.ncbi.nlm.nih.gov/31837645/ PMID: 31837645(https://pubmed.ncbi.nlm.nih.gov/31837645/)
[7]: https://pubmed.ncbi.nlm.nih.gov/32974211/ PMID: 32974211(https://pubmed.ncbi.nlm.nih.gov/32974211/)
[8]: https://pubmed.ncbi.nlm.nih.gov/34567890/ PMID: 34567890(https://pubmed.ncbi.nlm.nih.gov/34567890/)
See Also
- [KCNC1 Gene](/kcnc1-gene)
- Kv3.2 Protein
- Kv3.3 Protein
- Fast-Spiking Interneurons
- Parvalbumin
- [Epilepsy](/diseases/epilepsy)
- [Ataxia](/diseases/ataxia)
External Links
- [UniProt: KCNC1](https://www.uniprot.org/uniprot/P48547)
- [PDB: KCNC1](https://www.rcsb.org/structure/5W2Y)
- [GeneCards: KCNC1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNC1)
- [NCBI Gene: KCNC1](https://www.ncbi.nlm.nih.gov/gene/3748)